New treatment could save 1,000
A new method of delivering anti-cancer drugs to patients after bowel cancer surgery might prevent about 1,000 deaths a year in the UK, the Imperial Cancer Research Fund says today.
The new approach, of feeding drugs directly into the liver, through a tube inserted during surgery (portal vein infusion), means that more of the drug reaches this gland than when drugs are delivered in the normal way - by mouth or injecting them into the bloodstream. Reaching the liver is essential because it is the most common site for recurrence of bowel cancer, which kills 18,000 people a year in the UK and is the second leading cause of cancer deaths.
Researchers at the charity's Cancer Studies Unit in Oxford carried out a review of data on 4,000 patients in 10 studies world-wide and found that portal vein infusion appeared to reduce deaths by 5 per cent. Professor Richard Peto, the unit's head, said: "PVI is an unusually convenient cancer treatment. It's given for just one week after surgery and has few major side-effects."
Portal Vein Chemotherapy for Colorectal Cancer, Journal of the National Cancer Institute, 2 April 1997. Annabel Ferriman
Subscribe to Independent Premium to bookmark this article
Want to bookmark your favourite articles and stories to read or reference later? Start your Independent Premium subscription today.
Join our commenting forum
Join thought-provoking conversations, follow other Independent readers and see their replies